Posted yesterday in Pharmaceutical News

Weekly Drug News Round-Up: December 21, 2016

Rubraca Gets Early Accelerated Approval for Ovarian Cancer Roughly 15 to 20 percent of patients with ovarian cancer have a BRCA gene mutation Read More... In an end-of-year approval, the U.S. Food and Drug Administration (FDA) has cleared Clovis Oncology's Rubraca (rucaparib), over two months early, for the treatment of advanced mutant BRCA ovarian...

Posted today in Medical

Health Tip: Care for Yourself

-- In this busy world, making time to take care of yourself often falls by the wayside. The American Academy of Family Physicians mentions these benefits of better self-care: Having greater control over your health. Improving fitness and energy. Creating a more optimistic view and enjoying life more. Being a healthy role model for friends and...

Posted today in Medical

Where Medical Pot Is Legal, Fatal Car Crashes Often Decline

Traffic deaths have fallen in many -- but not all -- states with medical marijuana laws, a new study finds. The reason for this trend isn't clear, but the effect was most pronounced in younger drivers. That could mean that as marijuana becomes more easily accessible, more young people use it instead of alcohol, driving down drunk-driving rates, the...

Posted 2 days ago in New Drug Approvals

FDA Grants Accelerated Approval to Rubraca (rucaparib) for Advanced Ovarian Cancer

The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved...

Posted 2 days ago in New Drug Approvals

Novo Nordisk Receives FDA Approval of Tresiba (insulin degludec) for Use in Children and Adolescents With Diabetes

Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Tresiba® (insulin degludec injection 100 U/mL, 200 U/mL), a once-daily, long-acting basal insulin, to be used in children and adolescents with diabetes. Tresiba®, first approved by the FDA in September...

Posted 2 days ago in Clinical Trials

Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA

Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for PTSD, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TNX-102 SL* for the treatment of posttraumatic stress disorder (PTSD). The benefits of Breakthrough Therapy designation...

Posted today in Medical

Health Highlights: Dec. 21, 2016

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Young Adults' Cocaine Use Rises in 16 States Nearly 1 in 20 young adults in the United States use cocaine, a federal government study says. In 2014-15, 4.9 percent of adults ages 18-25 reported past-year use of the drug. Rates were unchanged in...

Posted today in Medical

Health Tip: What's Behind My Foot Arthritis?

-- The stiffness and pain that accompany arthritis are particularly noticable when they affect the feet. Here are possible reasons behind foot arthritis, courtesy of the American Podiatric Medical Association: Foot injuries, particularly if they were not treated properly. Viral or bacterial infections that affect the joints. Inflammatory bowel...

Posted today in Medical

Don't Forget Child Safety When Traveling for the Holidays

Parents of young children may leave some aspects of child safety behind when they hit the road for the holidays, a new study finds. "Parents are typically vigilant about safety measures, making sure toddlers are always in car seats and that medications and cleaning supplies are locked up or out of reach. But they may be less fastidious while on vacation,...

Posted today in Medical

U.S. Melanoma Rate Is Rising, Study Finds

More Americans are developing the potentially deadly skin cancer known as melanoma than in the past, new research shows. In 2016, one out of every 54 Americans was expected to develop a potentially lethal, invasive melanoma over their lifetime -- up from the one in 58 estimate when the same tally was performed in 2009. Overall, an estimated 76,380...

Recently added consumer and prescribing information: Rubraca, Eucrisa, Soliqua, Xultophy, Intrarosa, Vemlidy, Zinplava, Yosprala, Troxyca ER, Adlyxin

Posted in Blog

REMS@FDA: An Upgraded Patient Safety Program

REMS Overview Fact: Prescription drugs are complicated, and they are getting more complicated every day. Issues with complex drugs and side effects is not just a concern for the healthcare provider, it directly impacts the patient and caregiver, too. We’ve all heard the long list of adverse effects and warnings that unfold during a primetime […]

Posted in Blog

Drugs.com the First Major Consumer Health Publisher to Implement Full HTTPS Encryption

Drugs.com is pleased to announce the introduction of full HTTPS encryption for all web site visitors. With this significant and important change, nearly 70 million monthly visitors will have access to critical health and medicine information in a safe, secure and private environment. Why HTTPS Encryption? Almost everything you do on the Internet leaves a digital […]

Posted in Blog

Off-Label or Off-Limits? Should You Use A Drug For An Unapproved Use?

Off-Label Drug Use: What Is It? You may be surprised to learn that you have probably been prescribed a medication “off-label” at one point or another by your doctor. Maybe you’ve heard of “off-label” drug use in the news, but what does this really mean? “Off-label” use of a drug refers to prescribing a medication […]